SynthesisFrontiers in oncology2026
Oncology research in the kingdom of Bahrain: a four-decade bibliometric evolution.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bahrain reports the highest age-standardized cancer incidence among Gulf Cooperation Council (GCC) countries, but its oncology research output has not been comprehensively mapped. We profiled four decades of Bahrain-linked cancer publications to describe growth, contributors, collaboration, impact, and gaps. Methods: We searched Scopus and PubMed from inception to December 2024 using cancer-related terms combined with "Bahrain". We included articles, reviews, editorials, letters, conference papers, and book chapters. After deduplication, screening, and manual supplementation, 502 publications were analyzed by year, document type, journal quartile, SCImago Journal Rank (SJR), Bahraini authorship and first-author affiliation, geographic scope, study design, citations, and cancer site grouped using the ICD-O (3rd edition). Results: The first indexed paper appeared in 1981. Output was low until 2010, then increased sharply; 77.7% of publications appeared from 2011 to 2024, peaking at 66 papers in 2024. Articles accounted for 69.3% of the outputs, and reviews accounted for 21.7%, with greater diversity after 2010. The Bahrain Medical Bulletin was the most common outlet (20.2%). Salmaniya Medical Complex led in first-author output, followed by Arabian Gulf University and King Hamad University Hospital. Bahraini first authorship was observed in 66.7% of papers, and most studies were conducted exclusively in Bahrain (65.3%), although the proportion of global collaborations increased to 17.0% from 2021 to 2024. Descriptive designs predominated (57%, including 25.5% case reports), whereas analytic studies were uncommon (4.3%). Breast cancer was the most studied site-specific cancer (23.3%), followed by digestive organ cancers (11.4%); 27.1% of the papers addressed "unspecified" cancer. Respiratory and intrathoracic cancers remain persistently underrepresented despite a high mortality burden. Journal quality improved after 2010, reflected by increasing Q1/Q2 representation and higher SJR distributions. The citation peaks from 2014 to 2018 were driven by highly cited multinational collaborative publications. Conclusions: Bahrain's oncology research output has increased more than 30-fold over four decades, with expanding institutional participation and increasing international collaboration. Persistent reliance on descriptive designs and gaps in high-burden cancers-especially lung cancer-highlights priorities for capacity building, targeted funding, and a nationally aligned oncology research agenda for policy action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.